PDLIM7 and neoplasm: To examine whether these tumor variant point mutations or CTAR regions are required for LMP1 to regulate miR-155 or miR-193b, we utilized chimeric B95.8 NGFR.LMP1 molecules modified to contain mutations in CTAR1 (CTAR1mut) or CTAR2 (CTAR2mut), or both tumor variant point mutations (DM; Lambert and Martinez, 2007; Vaysberg et al., 2008).